ORIX Life Begins Offering Medical Insurance “CURE Next” and “CURE Lady Next,” Providing Enhanced Medical Insurance Coverage for Three Major Diseases to Vigorously Support the “Wish to Heal”

TOKYO, Japan - February 14, 2022 - ORIX Life Insurance Corporation (“ORIX Life”) announced today that it has redesigned its leading products, medical insurance “New CURE” and medical insurance “New CURE Lady,”^*1 and will begin offering medical insurance “CURE Next” and medical insurance “CURE Lady Next” (collectively “CURE Next”) on April 2, 2022.

The concepts behind medical insurance “CURE” are “Simple and easy-to-understand” and “Providing reasonable coverage at an affordable price.” As best-selling products of the Company, they have been supported by many customers with more than two million insurance policies in force^*2 since being launched in September 2006. The new “CURE Next” products to be offered this time, while inheriting the concepts of the existing products, have evolved into products that can provide enhanced coverage for three major diseases (cancer^*3, heart disease, and cerebrovascular disease).
It is said that, due to advances in medical technology, the three major diseases are becoming curable diseases. On the other hand, the average life expectancy will increase with the arrival of the 100-year life, and the risk of developing the diseases will tend to increase with age. Also, in many cases the financial burden will become greater due to prolonged hospitalization and treatment. In that context, by enhancing coverage for the three major diseases while keeping premiums affordable, “CURE Next” will more vigorously support customers’ “Wish to heal.”

ORIX Life will continue to provide offerings that meet the needs of the times, and will strive to continue to be an insurance company chosen by many customers.

[Main Points of Redesign]
(1) Enhanced coverage for three major diseases
As well as expanding the scope of coverage of the special provision for waiver of premium payment and three diseases lump-sum benefit to include “heart disease” and “cerebrovascular disease," “intraepithelial neoplasms” has been added to the scope of coverage of the special provision for waiver of premium payment.
(2) Death benefits can also be provided
It is possible to add a “whole life insurance rider” to provide both medical coverage and lifetime death benefits in a single policy.
(3) The coverage remains simple and easy-to-understand, and the premiums affordable
With the concepts of the medical insurance “CURE” series being retained, while the scope of coverage has been expanded, it is simple and easy-to-understand and provides reasonable coverage at an affordable price.

*1 Sale of medical insurance “New CURE” and medical insurance “New CURE Lady” will cease on April 1, 2022.
*2 The number of “CURE” and “CURE Lady” (launched in 2006) and “New CURE” and “New CURE Lady” (launched in 2013) insurance policies in force as of September 2021.
*3 Including intraepithelial neoplasms.

Contact Information:
Investor Relations and Sustainability Department
ORIX Corporation
Tel: +81-3-3435-3121

About ORIX:
ORIX Corporation (TSE: 8591; NYSE: IX) is a financial services group which provides innovative products and services to its customers by constantly pursuing new businesses.
Established in 1964, from its start in the leasing business, ORIX has advanced into neighboring fields and at present has expanded into lending, investment, life insurance, banking, asset management, automobile related, real estate and environment and energy related businesses. Since entering Hong Kong in 1971, ORIX has spread its businesses globally by establishing locations in 28 countries and regions across the world.
Going forward, ORIX intends to utilize its strengths and expertise, which generate new value, to establish an independent ORIX business model that continues to evolve perpetually. In this way, ORIX will engage in business activities that instill vitality in its companies and workforce, and thereby contribute to society. For more details, please visit our website: https://www.orix.co.jp/grp/en/
(As of September 30, 2021)

Caution Concerning Forward Looking Statements:
These documents May contain forward-looking statements about expected future events and financial results that involve risks and uncertainties. Such statements are based on our current expectations and are subject to uncertainties and risks that could cause actual results that differ materially from those described in the forward-looking statements. Factors that could cause such a difference include, but are not limited to, those described under “Risk Factors” in the Company’s annual report on Form 20-F filed with the United States Securities and Exchange Commission and under “(4) Risk Factors” of the “1. Summary of Consolidated Financial Results” of the “Consolidated Financial Results April 1, 2020 – March 31, 2021.”